These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 24885767)
1. Enhancing medicine price transparency through price information mechanisms. Hinsch M; Kaddar M; Schmitt S Global Health; 2014 May; 10():34. PubMed ID: 24885767 [TBL] [Abstract][Full Text] [Related]
2. Determinants of branded prescription medicine prices in OECD countries. Kanavos PG; Vandoros S Health Econ Policy Law; 2011 Jul; 6(3):337-67. PubMed ID: 21676345 [TBL] [Abstract][Full Text] [Related]
3. Price comparison of high-cost originator medicines in European countries. Vogler S; Zimmermann N; Babar ZU Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050 [TBL] [Abstract][Full Text] [Related]
5. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis. Moodley R; Suleman F BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977 [TBL] [Abstract][Full Text] [Related]
6. The 'Netflix plus model': can subscription financing improve access to medicines in low- and middle-income countries? Cherla A; Howard N; Mossialos E Health Econ Policy Law; 2021 Apr; 16(2):113-123. PubMed ID: 32122423 [TBL] [Abstract][Full Text] [Related]
7. Review of studies reporting actual prices for medicines. Mardetko N; Kos M; Vogler S Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):159-179. PubMed ID: 30468097 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology. Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276 [TBL] [Abstract][Full Text] [Related]
9. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134 [TBL] [Abstract][Full Text] [Related]
10. An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012. Lee JSF; Sagaon Teyssier L; Dongmo Nguimfack B; Collins IJ; Lallemant M; Perriens J; Moatti JP BMC Pediatr; 2016 Mar; 16():41. PubMed ID: 26979974 [TBL] [Abstract][Full Text] [Related]
11. Price discrimination in essential medicines: evidence from International Drug Price Indicator Guide data. Hanlon M; Zhang R Int Health; 2013 Mar; 5(1):58-63. PubMed ID: 24029847 [TBL] [Abstract][Full Text] [Related]
12. Short- and long-term impacts of the National Essential Medicines Policy on drug availability, price, and usage in a deprived rural county in southwestern China: an interrupted time series analysis across 8 years. Xiong X; Huo Z; Zhou S; Bai G; He S; Zhou Y; Jia J; Quan J; Luo L Front Public Health; 2024; 12():1355239. PubMed ID: 39267638 [TBL] [Abstract][Full Text] [Related]
13. Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines? Srivastava D; McGuire A BMC Public Health; 2014 Jul; 14():767. PubMed ID: 25073407 [TBL] [Abstract][Full Text] [Related]
14. Pricing and availability of some essential child specific medicines in Odisha. Swain TR; Rath B; Dehury S; Tarai A; Das P; Samal R; Samal S; Nayak H Indian J Pharmacol; 2015; 47(5):496-501. PubMed ID: 26600637 [TBL] [Abstract][Full Text] [Related]
15. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China. Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348 [TBL] [Abstract][Full Text] [Related]
16. The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico. Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV Value Health Reg Issues; 2019 Dec; 20():129-135. PubMed ID: 31374426 [TBL] [Abstract][Full Text] [Related]
17. Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices. Shaw B; Mestre-Ferrandiz J Pharmacoeconomics; 2020 Feb; 38(2):125-134. PubMed ID: 31956967 [TBL] [Abstract][Full Text] [Related]
18. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Mendis S; Fukino K; Cameron A; Laing R; Filipe A; Khatib O; Leowski J; Ewen M Bull World Health Organ; 2007 Apr; 85(4):279-88. PubMed ID: 17546309 [TBL] [Abstract][Full Text] [Related]
19. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price. Roughead EE; Kim DS; Ong B; Kemp-Casey A WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668 [TBL] [Abstract][Full Text] [Related]
20. Evaluating essential medicines for treating childhood cancers: availability, price and affordability study in Ghana. Mensah KB; Mensah ABB; Bangalee V; Padayachee N; Oosthuizen F BMC Cancer; 2021 Jun; 21(1):683. PubMed ID: 34112117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]